Dopavision is pioneering the development of digital therapeutics in ophthalmology. The Berlin-based start-up is developing a digital therapeutic for childhood myopia which can be easily administered using a smartphone app. Dopavision’s goal is to provide a clinically validated therapy to help fight the global myopia crisis. Myopia is the inability to see far away objects clearly. It commonly occurs due to excessive elongation of the eyeball during growth. This elongation causes incoming images to be focussed in front of the retina rather than on the retina. Myopia is a recognized public health concern, expected to reach a global prevalence of 50% by 2050. Severe cases of myopia are associated with chronic sight-threatening conditions, including glaucoma, cataract, retinal detachment, and myopic maculopathy. Dopavision’s breakthrough technology targets children and young adolescents to address myopia early on and provide medical benefits for later years of life. The Company’s lead product, MyopiaX®, leverages a patented, light-based technology that stimulates specific photosensitive cells of the retina, which in turn modulate retinal dopamine, a key neurotransmitter involved in eye growth. Founded in 2017, Dopavision GmbH has raised €14.7 million in private equity and public grants, and is backed by Seventure Partners, Novartis Pharmaceuticals, Boehringer Ingelheim Venture Fund, and Ababax Health. Dopavision is also supported by the German Federal Ministry of Education and Research (BMBF) via the “Industrie-in-Klinik” program. Proceeds from the Company’s €12 million Series A financing round, which closed in July 2021, will be used to fund the clinical development of MyopiaX®, as well as ongoing scientific research and product development activities.